1375637-35-6
1375637-35-6
Chemical Structure
LY2880070
- CAS No.: 1375637-35-6
- Formula:C19H23N7O2
- Molecular Weight:381.43
IUPAC Name: (R)-N-(5-(2-methoxy-6-methylpyridin-3-yl)-1H-pyrazol-3-yl)-6-(piperidin-3-yloxy)pyrazin-2-amine
InChIKey: LAEFIEWPUJMANC-CYBMUJFWSA-N
SMILES: COC1=C(C=CC(C)=N1)C2=CC(NC3=NC(O[C@@H]4CCCNC4)=CN=C3)=NN2
Biological Activity: LY2880070 is an orally active CHK1 inhibitor, IC50 ＜ 1 nM. LY2880070 can be used as an anticancer agent for combination with DNA damaging agents[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
LY2880070 | 99.9% | LY2880070 is an orally active CHK1 inhibitor, IC50 ＜ 1 nM. LY2880070 can be used as an anticancer agent for combination with DNA damaging agents. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Quincy S, et al. A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 2020 38:15_suppl, 3581.
- [2]. Kailong Jiang, et al. Functions and inhibitors of CHK1 in cancer therapy. Medicine in Drug Discovery. Volume 22, June 2024, 100185.
